GrowthCap’s Post

Time is running out: Register now for the 24th BioEquity Europe, May 12-14 in San Sebastian, Spain. Join more than 280 CEOs and 260 investors at this destination event for biopharma decision-makers. ✅ Register (don't wait, it will sell out): https://lnkd.in/gSxxhu7 One area to highlight: Half the 130 presenting biotechs are new to the BioEquity stage. If you are an investor or BD&L leader, BioEquity is where you meet newcos that have caught the eye of BioCentury Inc. (and my colleague Jeff Cranmer). A few examples: ➢ Alder Therapeutics ➢ Ananda Scientific ➢ BioCorteX ➢ Bloomsbury Genetic Therapies ➢ Cellaïon ➢ Cumulus Oncology ➢ Curadh MTR Inc ➢ Gate2Brain ➢ Kudo Biotechnology ➢ Kynos Therapeutics ➢ Laverock Therapeutics ➢ MitoRx Therapeutics ➢ Oniria Therapeutics ➢ Sapient Therapeutics ➢ Serna Bio ➢ TAUC3 BIOLOGICS ➢ Tessellate BIO ➢ Traverse Biotech, Inc ➢ and many more.... ✅ Visit the Presenting Company Dashboard to review their pipelines, financings, deals, and more: https://lnkd.in/ducEqTW3 Please send a DM if you have questions about the event. I hope to see you in San Sebastian! #biotech #biopharma #venturecapital #drugdevelopment #businessdevelopment #pharma #BioEquityEurope

Check out Proactive's research note that delves into some of our key programmes, each targetting large addressable markets such as #oncology, #flu, #RSV, #obesity and more.   The piece also covers our recent collaboration with a Nasdaq listed biopharma💊 using our oral delivery technology.   Read it here ⬇️ https://lnkd.in/epAmzseE

After productive time off including a trip to the Biotechnology Innovation Organization Conference in San Diego we're back with the next episode of #BioBlast!👏 👏 👏 Devin Zitelman connects with Carsten Brunn, President & CEO, Cartesian Therapeutics (NASDAQ: RNAC), a publicly traded, clinical-stage #biotech company pioneering #mRNA cell therapy for autoimmune diseases. The two discuss the company's $110M reverse-merger with Selecta Biosciences, plus: 🔎 Professional story and career "arcs" that inform his leadership style and management approach. ☕ The integration of founder (Murat Kalayoglu + Michael Singer) and executive teams, approach to culture-building and talent acquisition. 💉 Managing a pipeline of novel assets across multiple indications and phases of clinical trials. 🔭 Differences and advantages of hosting operations in #Boston and #Maryland including their biomanufacturing + GMP facilities. 💰 Trends in venture and development capital. ...and more! 📹 Tune in and subscribe to #BioBlast, now streaming on YouTube & Spotify for Podcasters plus anywhere you access your #podcasts. MassBio Maryland Tech Council Maryland Department of Commerce BioBuzz Nasdaq Frederick Innovative Technology Center, Inc Argot Partners Scheer Partners Velogic The National Institutes of Health Disclaimer: The views expressed in this promotion are based on personal opinions and should not be considered investment advice. Scheer Partners employs individuals that own shares in Cartesian Therapeutics stock.

Tune into the next episode of #BioBlast with Carsten Brunn of Cartesian Therapeutics! We appreciate your time, and for sharing insights on the highly relevant trends impacting #biotech and #pharma in 2024 and beyond.

Where does the power lie in Quince Therapeutics’ platform? It’s in our ability to harness a patient’s own biology with our proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology to deliver innovative therapeutics to those living with rare diseases.   We invite you to listen in as Dirk Thye, Quince’s CEO & CMO, describes what makes the AIDE technology behind our Phase 3 lead asset, EryDex, so powerful. By pioneering the delivery of drugs encapsulated in a patient’s own red blood cells, we’re looking to redefine the standard of care, first for chronic corticosteroid therapy, and later for other drugs, that will and meaningfully improve the quality of life for rare disease patients and their families.   For more information on Quince Therapeutics, contact [email protected].   #Biotech #Raredisease #Innovation

Looking back at the past 30 years, I remember myself doing science about 55-60 hours a week, and then helping venture capitalists and biotech start-ups about 70-80 h/week. Usually unsatisfied, sometimes exhausted, but pleased overall. This overexciting workaholism was somehow interrupted last year. I had less work and a lot of mountaineering, - climbed about 5.5 Chomolungma attitudes during the year. It feels like I have reached the stage at which it is a time to start sharing experiences and understanding of the universe. This week, I started to share by publishing an analytic report at SeekigAlpha about TG Therapeutics. This small biotech company has developed a third-to-market anti-CD20 mAb for the treatment of multiple sclerosis (MS). Along with the company, this report briefly touches upon current treatments for MS, the competitive landscape of therapeutics, and the uncertainties surrounding the development of new BTK inhibitors. https://lnkd.in/drAFx9vt

The latest episode of Raising Biotech is up, this time with Sparrow Pharmaceuticals, Inc. In this episode we learn that it's never too late to start a biotech as David A. Katz, founded Sparrow when he "should" have been retiring. David was able to raise $50 million in a Series A in 2020 to help fight the long standing (yet often forgotten) problem of patients suffering from steroid excess -- either from cortisol secreting tumors in Cushing's Syndrome or Autonomous Cortisol Secretion, or as side-effects from common glucocorticoid medications like prednisone and predisolone, which is pretty much every common autoimmune disease. This is another "trash to treasure" type story as David took a deprioritized drug out of a big pharma pipeline and is positioning it in three different clinical programs. David talks about his own journey as the company founder, what it was like to negotiate a drug license with big pharma, pitching to skeptical investors and he shares more details on each clinical trial program and future company visions. Also joining the podcast is Dr Peter Merkel, Chief of the Division of Rheumatology, Penn Medicine, University of Pennsylvania Health System as well as Dr Leon Henderson-MacLennan, MD, FACP, former medical internist and founder, inThought Research. These experienced experts give us more context on the drug's potential to fill an unmet need amidst an existing treatment landscape. This is quite an inspiring story, as it's taken a lot of patience and persistence to get Sparrow to this point and the company will soon be reaching an inflexion point as it plans for important data readouts this year. Listen (and find time stamps) here ⏯️: Apple: https://lnkd.in/eGTiXaye Spotify: https://lnkd.in/ezCyJCyB This episode is proud to be partnered with Mindgram - a research tool powered by AI serving the global biopharma community. Raising Biotech listeners are able to get an exclusive free trial (link in show notes). OrbiMed RiverVest Venture Partners USVP #venturecapital #steroids #glucocorticoids #cortisol #cushings #autoimmunedisease

With major collaborations and partnership deals involving companies like C4 Therapeutics, Inc. , Merck, Monte Rosa Therapeutics and more, and significant progress in the clinic with BTK degraders and other assets, it’s crucial to unite at the 7th TPD & Induced Proximity Summit taking place in Boston this October. The longest standing and most comprehensive protein degradation and proximity conference will span everything from foundational research and discovery to IND-filing and clinical trials, allowing a deep dive into the opportunities and challenges in expanding the target space and developing therapeutically relevant degraders, blockers, stabilisers, and inducers of protein-protein interactions. Uniting over 550 enthusiasts from across the field, we will be providing a comprehensive view of protein degradation and modulation research, including SureTACs, EpiTACs, RIPTACs, Molecular Gates, and more, allowing you to network with experts in the space, benchmark against competitors and stay ahead of the curve. 💬 Interested in getting involved? Email me at [email protected] or message me via LinkedIn and I will be happy to share the agenda! #proteindegradation #TPD #targetedproteindegradation #inducedproximity #WomenInTPD #molecularglues #partnershipsinTPD

That should better stick: molecular glue is one of the most exciting possible futures in #Biopharma and #Biotech Although I had already covered this topic almost 6 months ago (Link ➡ https://lnkd.in/dQiwuETe), recent events shed more lights on the growing interest by Big Pharma in the field, as well as the inherent challenges associated with next generations innovations. Growing interest by Big Pharma... Last week, Takeda signed a collaboration of up to $1.2bn with molecular glue young biotech company Degron Therapeutics (Link ➡https://lnkd.in/dFhiBZGe). Interestingly, the collaboration goes beyond oncology and extends into inflammation and neuroscience. This reminds us of the Roche and Monte Rosa Therapeutics collaboration of up to $2bn to co-develop pre-clinical programs in oncology and neuroscience, which was announced about 6 months ago (Link ➡ https://lnkd.in/dMnf5tcD). However, Monte Rosa Therapeutics has continued to be active in the BD&L and financing space. As Takeda was in the final stages of inking a deal with Degron Therapeutics, Monte Rosa Therapeutics announced a $100M follow-on offering on Nasdaq (Ticker $GLUE), in a mix of common shares and pre-funded warrants (a sign that the IPO market remains difficult right now). (Link ➡https://lnkd.in/d9s3aHZt) Some commentators have been questionning the move... With a treasure chest of c. $200M and a cash runway going well into year 2027, why would Monte Rosa Therapeutics raise an additional $100M when its share price is close to an all-time low? This brings us to the inherent challenge associated with such a disruptive innovation. As competition heats up and Big Pharma get more and more into the field, the investments required to stay in the lead will only grow wider. In that context, the definition of a cash runway is a fleeting and dangerous one, for corporate executives and investors alike. #Biotech #lifesciences #capitalmarkets #businessdevelopment #communication

Source. Plan. Invest. Execute. These sound like simple directions, but in the context of pre-seed therapeutics investment the route can be hard to navigate. In the next chapter of Evotec’s White Paper series, ‘From academic concept to commercial reality: How to accelerate translational drug discovery’ we take a look from an investor’s perspective at the way-markers for a successful translational roadmap. Read chapter 2, 'Source. Plan. Invest. Execute. Navigating the tough roadmap of pre-seed therapeutics investment' here - https://hubs.ly/Q02j-Bfx0 #researchneverstops